ANGPTL3 and Hepatic steatosis: A beneficial effect of ANGPTL3 inhibition on insulin resistance and fatty liver has been suggested (109, 118); however, liver-targeted antisense inhibition of ANGPTL3 with vupanorsen in subjects with fasting hypertriglyceridemia and increased liver fat, while lowering TG levels by about 60%, did not result in reduced steatosis or improved glycemic parameters (119).